CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
65.55
-1.27 (-1.90%)
At close: Apr 28, 2026, 4:00 PM EDT
65.55
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:05 PM EDT
CG Oncology Stock Forecast
Stock Price Forecast
The 11 analysts that cover CG Oncology stock have a consensus rating of "Strong Buy" and an average price target of $77.64, which forecasts a 18.44% increase in the stock price over the next year. The lowest target is $50 and the highest is $100.
Price Target: $77.64 (+18.44%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $73 → $79 | Buy | Maintains | $73 → $79 | +20.52% | Apr 27, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $65 → $91 | Buy | Maintains | $65 → $91 | +38.83% | Apr 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $100 | Strong Buy | Maintains | $80 → $100 | +52.56% | Apr 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $80 | Strong Buy | Maintains | $75 → $80 | +22.04% | Feb 27, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $66 → $75 | Strong Buy | Maintains | $66 → $75 | +14.42% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
17.70M
from 4.04M
Increased by 338.00%
Revenue Next Year
135.98M
from 17.70M
Increased by 668.47%
EPS This Year
-2.57
from -2.08
EPS Next Year
-2.10
from -2.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 109.5M | 441.9M | ||||||
| Avg | 17.7M | 136.0M | ||||||
| Low | n/a | 24.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2,611.1% | 2,397.3% | ||||||
| Avg | 338.0% | 668.5% | ||||||
| Low | - | 38.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.64 | -0.24 | ||||||
| Avg | -2.57 | -2.10 | ||||||
| Low | -3.16 | -2.92 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.